Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.65 |
| ▸ | JAK3 | P52333 | 11/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342122 | 0.86 | JAK2 (0.67) | JAK2JAK3KCNH2RAF1BRAF | |
| SCHEMBL3006004 | 0.86 | JAK2 (0.67) | JAK2JAK3KCNH2RAF1BRAF | |
| SCHEMBL4421973 | 0.81 | JAK2 (0.54) | JAK2JAK3KCNH2MAPTNTRK1 | |
| SCHEMBL2160844 | 0.81 | JAK2 (0.54) | JAK2JAK3KCNH2MAPTNTRK1 | |
| SCHEMBL2338534 | 0.80 | JAK2 (0.65) | JAK2JAK3KCNH2NTRK1 | |
| SCHEMBL3671795 | 0.80 | JAK2 (0.65) | JAK2JAK3KCNH2NTRK1 | |
| SCHEMBL13494392 | 0.80 | JAK3 (0.71) | JAK2JAK3KCNH2NTRK1JAK1 | |
| SCHEMBL2339473 | 0.79 | JAK2 (1.00) | JAK2JAK3KCNH2NTRK1JAK1 | |
| SCHEMBL220863 | 0.78 | JAK3 (1.00) | JAK2JAK3KCNH2NTRK1JAK1 | |
| SCHEMBL2161854 | 0.77 | JAK2 (0.54) | JAK2JAK3KCNH2MAPTNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152702-B1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, TYMP, TPMT | JAK2 8/4885JAK3 31/4885KCNH2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.